Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease

NeuroSignals

Volumn 14, Issue 1-2, 2005, Pages 6-22

  Houghton, Peter J ^a   Howes, Melanie Jayne ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b JODRELL LABORATORY   (United Kingdom)

Author keywords

Acetylcholine; Alzheimer's disease; Cholinergic receptors; Cholinesterase inhibitors; Dopamine; Dopaminergic receptors; Ergot alkaloids; Galantamine; Huperzine; L DOPA; Parkinson's disease; Physostigmine

Indexed keywords

ACETYLCHOLINE; ALVAMELINE; ARECOLINE; BANISTERIOPSIS CAAPI EXTRACT; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CHOLINESTERASE INHIBITOR; CLAVICEPS PURPUREA EXTRACT; COPTIS CHINENSIS EXTRACT; DONEPEZIL; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT ALKALOID; GALANTAMINE; GINKGO BILOBA EXTRACT; HUPERZINE A; HYPERICUM PERFORATUM EXTRACT; LEVODOPA; LISURIDE; MAGNOLIA OFFICINALIS EXTRACT; MELISSA OFFICINALIS EXTRACT; MONOAMINE OXIDASE INHIBITOR; MUCUNA PRURIENS EXTRACT; MUSCARINIC M1 RECEPTOR AGONIST; NATURAL PRODUCT; NEOSTIGMINE; NEUROTRANSMITTER; ORIGANUM MAJORANA EXTRACT; PERGOLIDE; PHYSOSTIGMINE; PILOCARPINE; PLANT EXTRACT; RIVASTIGMINE; SALSOLINOL; SALVIA LAVANDULAEFOLIA EXTRACT; SALVIA MILTIORRHIZA EXTRACT; SALVIA OFFICINALIS EXTRACT; TACRINE; TALSACLIDINE; UNCLASSIFIED DRUG; WITHANIA SOMNIFERA EXTRACT;

ALZHEIMER DISEASE; BANISTERIOPSIS; COGNITION; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG EFFICACY; GINKGO BILOBA; HUMAN; HYPERICUM PERFORATUM; MEMORY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW; SUBSTANTIA NIGRA; TRADITIONAL MEDICINE; WITHANIA SOMNIFERA;

ACETYLCHOLINE; ALZHEIMER DISEASE; ANIMALS; DOPAMINE; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE; PLANT EXTRACTS; SYNAPTIC TRANSMISSION; UP-REGULATION;

EID: 20944441667     PISSN: 1424862X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085382     Document Type: Review

References (112)

1. http://www.alzheimers.org.uk/Facts_about_dementia/index.htm July 2004.
2. http://www.who.int/mediacentre/factsheets/fs218/en/ August 2004.
3. Howes M-JR, Houghton PJ: Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharm Biochem Behavior 2003;75:513-527.
4. Howes M-JR, Perry NSL, Houghton PJ: Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother Res 2003;17:1-18.
5. Francis PT, Palmer AM, Snape M, et al: The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-147.
6. Desgranges B, Baron J-C, de la Sayette V, et al: The neural substrates of memory systems impairment in Alzheimer's disease. Brain 1998;121:611-631.
7. Förstl H, Hentschel F, Sattel H, et al: Age-associated memory impairment and early Alzheimer' disease. Drug Res 1995;45:394-397.
8. McGuffey EC: Alzheimer's disease: An overview for the pharmacist. JAMA 1997;NS37:347-352.
9. Perry E, Tomlinson E, Blessed G, et al: Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978;2:1457-1459.
10. Giacobini E: The cholinergic system in Alzheimer disease. Prog Brain Res 1990;84:321-332.
11. Balfour DJK, Fagerström KO: Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther 1996;72:51-81.
12. Whitehouse PJ, Kalaria RN: Nicotinic receptors and neurodegenerative dementing diseases: Basic research and clinical implications. Alzheimer Dis Assoc Disord 1995:9(suppl 2):3-5.
13. Avery EE, Baker LD, Asthana S: Potential role of muscarinic agonists in Alzheimers disease. Drugs Aging 1997;11:450-459.
14. Bratt AM, Kelly ME, Domeney AM, et al: Acute and chronic arecoline: Effects of a scopolamine-induced deficit in complex maze learning. Pharm Pharmacol Behav 1996;53:713-721.
15. Yang YR, Chang KC, Chen CL, et al: Arecoline excites rat locus coerulus neurons by activating the M-2-muscarinic receptor. Chin J Physiol 2000;43:23-28.
16. Soncrant TT, Raffaele KC, Asthana S, et al: Memory improvement without toxicity during chronic, low-dose intravenous arecoline in Alzheimers disease. Psychopharmacology 1993;112:421-427.
17. Meier E, Frederiksen K, Nielsen M, et al: Pharmacological in vitro characterization of the arecoline bioisostere Lu 25-109-T, a muscarinic compound with M-1-agonistic and M-2/M-3 antagonistic properties. Drug Dev Res 1997;40:1-16.
18. Tlal LJ, Forreest M, Loft H, et al: Lu-25-109, a muscarinic agent, fails to improve cognition in Alzheimer's disease. Neurology 2000;54:421-426.
19. Wienrich M, Meier D, Ensinger HA, et al: Pharmacodynamic profile of the M-1 agonist talsclidine in animals and man. Life Sci 2001; 22:2593-2600.
20. Terry AV, Buccafusco JJ, Borsini F, et al: Memory-related performance by aged rhesus monkeys administered the muscarinic M-1-preferring agonist, talsaclidine. Psychopharmacology 2002;162:292-300.
21. Levin ED, Torry D: Acute and chronic nicotine effects on working memory in aged rats. Psychopharmacology 1996;123:88-97.
22. McCaleb R: Nature's medicine for memory loss. HerbalGram 1990;23:15.
23. Sitaram N, Weingartner H, Gillin JC: Physostigmine: Improvement of long-term memory processes in normal humans. Science 1978;201:272-276.
24. Greig NH, Utsuki T, Yu QS, et al: A new therapeutic target in Alzheimer's disease treatment: Attention to butyrylcholinesterase. Curr Med Res Opin 2001;17:159-165.
25. Polinsky RJ: Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998;20:634-647.
26. Grossberg G, Desai A: Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders. Expert Opin Pharmacother 2001;2:653-666.
27. Spencer CM, Noble S: Rivastigmine - a review of its use in Alzheimer's disease. Drugs Aging 1998;13:391-411.
28. Bores GM, Huger FP, Petko W, et al: Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine. Am Soc Pharmacol Exp Ther 1996;277:728-738.
29. Heinrich M, Teoh HL: Galanthamine from snowdrop - the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. J Ethnopharmacol 2004;92: 147-162.
30. Wilcock GK, Lilienfeld S, Gaens E, on behalf of the Galantamine International-1 Study Group: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. BMJ 2000;321:1445-1449.
31. Wilkinson D, Murray J: Galantamine: A randomised, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2001;16:852-857.
32. Marcusson J, Bullock R, Gauthier S, et al: Galantamine demonstrates efficacy and safety in elderly patients with Alzheimer's disease. Alzheimer Dis Assoc Disord 2003;17S3:S86-S91.
33. Raskind MA, Peskind ER, Truyen L, et al: The cognitive benefits of galantamine are sustained for at least 36 months: A long term extension trial. Arch Neurol 2004;61:252-256.
34. Fulton B, Benfield P: Galantamine. Drugs Aging 1996;1:60-65.
35. Woodruff-Pak DS, Vogel RW, Wenk GL: Galantamine: Effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci 2001;98:2089-2094.
36. Small GW, Rabins RV, Barry PP, et al: Diagnosis and treatment of Alzheimer's disease and related disorders. JAMA 1997;278:1363-1371.
37. Lopez S, Bastida J, Viladomat F, et al: Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts. Life Sciences 2002;71:2521-2529.
38. Houghton PJ, Agbedahunsi JM, Adegbulugbe A: Choline esterase inhibitory properties of alkaloids from two Nigerian Crinum species. Phytochemistry 2004;65:2893-2896.
39. Skolnick AA: Old herbal Chinese medicine used for fever yields possible new Alzheimer disease therapy. JAMA 1997;277:776.
40. Wang Y-E, Yue D-X, Tang X-C: Anti-cholinesterase activity of huperzine A. Acta Pharm Sinica 1986;7:110-113.
41. Bai DL, Tang XC, He XC: Huperzine A, a potential therapeutic agent for treatment of Alzheimers disease. Curr Med Chem 2000;7:355-374.
42. Lu W-H, Shou J, Tang X-C: Improving effect of huperzine A in aged rats and adult rats with experimental cognitive impairment. Acta Pharm Sinica 1988;9:11-15.
43. Zhou J, Zhang HY, Tang XC: Huperzine A attenuates cognitive deficits and hippocampal neuronal damage after transient global ischemia in gerbils. Neurosci Lett 2001;313:137-140.
44. Xiao XQ, Zhang HY, Tang XC: Huperzine A attenuates amyloid β-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J Neurosci Res 2002;67:30-36.
45. Zhou J, Tang XC: Huperzine A attenuates apoptosis and mitochondria-dependent caspase-3 in rat cortical neurons. FEBS Lett 2002;526:21-25.
46. Zhang Z, Wang X, Chen Q, et al: Clinical efficacy and safety of huperzine alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomised trial. Chin Med J 2002;82:941-944.
47. Jiang H, Luo X, Bai D: Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A: A drug of traditional Chinese medicine origin, in the treatment of Alzheimer's disease. Curr Med Chem 2003;10:2231-2252.
48. Huang KC: The Pharmacology of Chinese Herbs. Boca Raton, CRC Press, 1993.
49. Shigeta K, Ootaki K, Tatemoto H, et al: Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by a Coptidis rhizoma extract and protoberberine alkaloids. Biosci Biotechnol Biochem 2002;66:2491-2494.
50. Hsieh MT, Peng WH, Wu CR, et al: The ameliorating effects of the cognitive-enhancing Chinese herbs on scopolamine-induced amnesia in rats. Phytother Res 2000;14:375-377.
51. Kuznetsova LP, Nikol'skaya EB, Sochilina EE, et al: Inhibition of human blood acetylcholinesterase and butyrylcholinesterase by some alkaloids. J Evol Biochem Physiol 2002;38:35-39.
52. Peng WH, Hsieh MT, Wu CR: Effect of long-term administration of berberine on scopolamine-induced amnesia in rats. Jpn J Pharmacol 1997;74:261-266.
53. Moon TC, Murakami M, Kudo I, et al: A new class of COX-2 inhibitor, rutaecarpine from Evodia rutaecarpa. Inflamm Res 1999;48:621-625.
54. Park CH, Kim S, Choi W, et al: Novel anticholinesterase and antiamnesic activities of dehydroevodiamine, a constituent of Evodia ruraecarpa. Planta Med 1996;62:405-409.
55. Haji A, Momose Y, Takeda R, et al: Increased feline cerebral blood flow induced by dehydroevodiamine hydrochloride from Evodia rutaecarpa. J Nat Prod 1994;57:387-389.
56. Krasowski MD, McGehee DS, Moss J: Natural inhibitors of cholinesterases: implications for adverse drug reactions. Can J Anaesth 1997;44:525-534.
57. Perry N, Court G, Bidet N, et al: European herbs with cholinergic activities: Potential in dementia therapy. Int J Geriatr Psychiatry 1996;11:1063-1069.
58. Perry NSL, Houghton PJ, Theobald A, et al: In vitro inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol 2000a;52:895-902.
59. Savelev S, Okello E, Perry NSL, et al: Synergistic and antagonistic interactions of anticholinesterase terpenoids in Salvia lavandulaefolia essential oil. Pharmacol Biochem Behav 2003;75:661-668.
60. Perry NSL, Houghton PJ, Jenner P, et al: Savia lavandulaefolia essential oil inhibits cholinesterase in vivo. Phytomedicine 2002;9:48-51.
61. Tildesley NTJ, Kennedy DO, Perry EK, et al: Salvia lavandulaefolia (Spanish sage) enhances memory in healthy young volunteers. Pharmacol Biochem Behav 2003;75:669-674.
62. Perry NSL, Bollen C, Perry EK, et al: Salvia for dementia therapy: Review of pharmacological activity and pilot tolerability clinical trial. Pharmacol Biochem Behav 2003;75:651-660.
63. Akhondzadeh S, Noroozian M, Mohammadi M, et al: Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: A double-blind, randomised and placebo-controlled trial. J Clin Pharm Ther 2003;28:53-59.
64. Yarnell E: Lemonbalm. Altern Complement Ther 1998;4:417-419.
65. Kennedy DO, Wake G, Savelev S, et al: Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. Neuropsychopharmacology 2003;28:1871-1881.
66. Akhondzadeh S, Noroozian M, Mohammadi S, et al: Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: A double blind, randomised, placebo controlled trial. J Neurol Neurosurg Psychiatry 2003;74:863-866.
67. Ryan MF, Byrne O: Plant-insect coevolution and inhibition of acetylcholinesterase. J Chem Ecol 1988;14:1965-1975.
68. Kuang P, Tao Y, Tian Y: Effect of radix Salviae miltiorrhizae on nitric oxide in cerebral ischemic-reperfusion injury. J Tradit Chin Med 1996a;16:224-227.
69. Ren Y, Houghton PJ, Hider RC, et al: Novel diterpenoid acetylcholinesterase inhibitors from Salvia miltiorrhiza. Planta Med 2004;70:201-204.
70. Chung YK, Heo HJ, Kim EK, et al: Inhibitory effect of ursolic acid purified from Origanum majorana L. on the acetylcholinesterase. Mol Cells 2001;11:137-143.
71. Ghosal S, Lal R, Srivastava SK, et al: Immunomodulatory and CNS effects of sitoindosides IX and X, two new glycowithanolides from Withania somnifera. Phytother Res 1989;3:201-206.
72. Schliebs R, Liebmann A, Bhattacharya SK, et al: administration of defined extracts from Withania somnifera (Indian ginseng) and shilajit differentially affects cholinergic but not glutamatergic markers in rat brain. Neurochem Int 1997;30:181-190.
73. Bhattacharya SK, Kumar A, Ghosal S: Effects of glycowithanolides from Withania somnifera on an animal model of Alzheimer's disease and perturbed central cholinergic markers of cognition in rats. Phytother Res 1995;9:110-113.
74. Bhattacharya A, Ramanathan M, Ghosal S, et al: Effect of Withania somnifera glycowithanolides on iron-induced hepatotoxicity in rats. Phytother Res 2000;14:568-570.
75. Parihar MS, Hemnani T: Phenolic antioxidants attenuate hippocampal neuronal cell damage against kainic acid induced excitotoxicity. J Biosci 2003;28:121-128.
76. Begum V, Sadique J: Long term effect of herbal drug Withania somnifera on adjuvant induced arthritis in rats. Ind J Exp Biol 1998;26:887-882.
77. Dhuley JN: Effect of some Indian herbs on macrophage functions in ochratoxin A treated mice. J Ethnopharmacol 1997;58:15-20.
78. Hou YC, Chao PD, Chen SY: Honokiol and magnolol increased hippocampal acetylcholine release in freely-moving rats. Am J Chin Med 2000;28:379-384.
79. Kuribara H, Kishi E, Hattori N, et al: The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from Magnolia bark. J Pharm Pharmacol 2000;52:1425-1429.
80. 3H]muscimol binding sites three-fold in rat forebrain membranes in vitro using a filtration assay, by allosterically increasing the affinities of low-affinity sites. Neurochem Res 1999;24:1593-1602.
81. Lo YC, Teng CM, Chen CF, et al: Magnolol and honokiol from Magnolia officinalis protect rat heart mitochondria against lipid peroxidation. Biochem Pharmacol 1994;47:549-553.
82. Wang LM, Mineshita S: Preventive effects of Unsei-in and Oren-gedoku-to, Chinese traditional medicines, against rat paw oedema and abdominal constriction in mice. J Pharm Pharmacol 1996;48:327-331.
83. Merchant C, Tang MX, Albert S, et al: The influence of smoking on the risk of Alzheimer's disease. Neurology 1999;52:1408-1412.
84. Ott A, Slooter AJC, Hofman A, et al: Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: The Rotterdam Study. Lancet 1998;351:1840-1843.
85. Salomon AR, Marcinowski KJ, Friedland RP, et al: Nicotine inhibits amyloid formation by the β-peptide. Biochemistry 1996;35:13568-13578.
86. Whitehouse PJ, Kalaria RN: Nicotinic receptors and neurodegenerative dementing diseases: Basic research and clinical implications. Alzheimer Dis Assoc Disord 1995;9(suppl 2):3-5.
87. Polya G: Biochemical Targets of Plant Bioactive Compounds. London, Taylor & Francis, 2003.
88. Decker MW, Majchrzak MJ, Arneric SP: Effects of lobeline, a nicotinic receptor agonist, on learning and memory. Pharmacol Biochem Behav 1993;45:571-576.
89. http://www.parkinsons.org.uk/Templates/]
90. Kidd PM: Parkinson's disease as multifactorial oxidative neurodegeneration: Implications for integrative management. Altern Med Rev 2000;5:502-529.
91. Hussain G, Manyam BV: Mucuna pruriens proves more effective than L-DOPA in parkinson's disease animal model. Phytother Res 1997;11:419-423.
92. Vaidya RA, Sheth AR, Alookar SD, et al: The inhibitory effect of the Cowhage plant - Mucuna pruriens - and L-DOPA on chlorpromazine-induced hyperprolactinaemia in man. Neurol India 1978;26:171-176.
93. Manyam BV, Dhanasekaran M, Hare TA: Effect of antiparkinson drug HP-200 (Mucuna pruriens) on the central monoaminergic neurotransmitters. Phytother Res 2004;18:97-101.
94. Al-Motarreb A, Baker K, Broadley KJ: Khat: Pharmacological and medical aspects and its social use in Yemen. Phytother Res 2002;16:403-413.
95. Ismail M: Pers commun, 2004.
96. Bonucelli U: Comparing dopamine agonists in Parkinson's disease. Curr Opin Neurology 2003;16:S13-S19.
97. Sit SY: Dopamine agonists in the treatment of Parkinson's disease. Past, present and future. Curr Pharm Design 2000;6:1211-1248.
98. Poewe W: Pergolide - a review of its clinical potential. Akt Neurol 1995;22:71-74.
99. Pastor P, Tolosa E: Cabergoline in the treatment of Parkinson's disease. Neurologia 2003;18:202-209.
100. Stocchi F: Dopamine agonists in Parkinson's disease - What is their role in early treatment? CNS Drugs 1998;10:159-170.
101. Melzig MF, Putscher I, Henklein P, et al: In vitro pharmacological activity of the tetrahydroisoquinoline salsinol present in products from Theobroma cacao L. like cocoa and chocolate. J Ethnopharmacol 2000;73:153-159.
102. Antkiewicz-Michaluk L, Wardas J, Michaluk J, et al: Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int J Neuropsychopharmacol 2004;7:153-163.
103. Naoi M, Maruyama W, Nagy GM: Dopamine-derived salsolinol derivatives as endogenous monoamineoxidase inhibitors: Occurrence, metabolism and function in human brains. Neurotoxicology 2004;25:193-204.
104. Harsing LG, Sershen H, Lajtha A: Evidence that ibogaine releases dopamine from the cytoplasmic pool in isolated mouse striatum. J Neural Transm 1994;96:215-225.
105. Mah SJ, Tang YM, Liauw PE, et al: Ibogaine acts at the nicotinic acetylcholine receptor to inhibit catecholamine release. Brain Res 1998;797:173-180.
106. Schwarz MJ, Houghton PJ, Rose S, et al: Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism. Pharmacol Biochem Behav 2003;75:627-633.
107. Wagner H, Bladt S: MAO inhibition by fractions and constituents of Hypericum extract. Nervenheilkunde 1993;12:349-352.
108. Sloley BD, Urichuk LJ, Morley P, et al: Identification of kaempferol as a monoamineoxidase inhibitor and potential neuroprotectant in extracts of Ginkgo biloba leaves. J Pharm Pharmacol 2000;52:451-459.
109. Singh A, Naidu PS, Kulkami SK: Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: Possible COMT/MAO inhibition. Pharmacology 2003;68:81-88.
110. Naidu PS, Kulkarni SK: Quercetin, a bioflavonoid, reverses haloperidol-induced catalepsy. Meth Findings Exp Clin Pharmacol 2004;26:323-326.
111. Datla KP, Christidou MA, Widmer WW, et al: Citrus flavonoid tangeretin accumulates in the brain and pre-treatment protects against dopaminergic neuronal loss in a rat model of Parkinson's disease. Br J Pharmacol 2002;135:350P.
112. Mandel S, Weinreb O, Amit T, et al: Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3- gallate: Implications for neurodegenerative diseases. J Neurochem 2004;88:1555-1569.